UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
Phase 2
Completed
- Conditions
- CarcinomaNon-Squamous Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 165
- Registration Number
- NCT00152477
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
Phase 3
Completed
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 392
- Registration Number
- NCT00152425
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
Phase 3
Completed
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 604
- Registration Number
- NCT00152490
Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS
Phase 3
Completed
- Conditions
- Epilepsy, Partial
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 192
- Registration Number
- NCT00152373
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
Phase 2
Completed
- Conditions
- Peptic Ulcer
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 370
- Registration Number
- NCT00152399
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 514
- Registration Number
- NCT00152464
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 255
- Registration Number
- NCT00152516
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 59
- Registration Number
- NCT00152503
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures
Phase 2
Completed
- Conditions
- Epilepsies, Partial
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 160
- Registration Number
- NCT00151879
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT00152412
© Copyright 2025. All Rights Reserved by MedPath